Flot.bio x Philip Hemme – Détails, épisodes et analyse

We’re in Munich 🇩🇪 with a “true” biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis. We talked about building a champion ADC biotech, the super hot ADC sphere, and the difference between luck and success.

💎 ABOUT THE SPEAKER

Dominik has had an incredible career, which he started from a young age. With the founding of Tubulis, he has won many start-up awards and in 2019 he was awarded MIT’s Innovators Under 35. As a life science investor, he has invested early in many European biotech companies. 🔗 LINKS MENTIONED - https://curie.bio/ - https://curie.bio - Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline - https://tubulis.com/news/tubulis-closes-upsized-e128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline/ - BioSpace - Next wave of ADCs - https://www.biospace.com/article/the-next-wave-of-adcs-could-treat-evasive-solid-tumors-/ - BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival - https://www.fiercebiotech.com/biotech/bms-axes-eisai-adc-pact-3-years-after-paying-650m-would-be-elahere-rival - Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - https://www.biospace.com/article/merck-s-adc-pact-with-daiichi-hits-regulatory-setback-with-fda-rejection/ - ADC Space is too crowded? - https://drive.google.com/file/d/1oA23bidvd2G-z2lnAkPLAMZgl1RXLtr9/view?usp=sharing - Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio ($1.8B cash) - https://ir.genmab.com/news-releases/news-release-details/genmab-broaden-and-strengthen-oncology-portfolio-acquisition - BIO-Europe Spring 2019: Newcomer Tubulis tackles ADC technology shortcomings - https://www.youtube.com/watch?v=wwr5KMypBHs - Top 20 Healthcare Specialist Investors - https://drive.google.com/file/d/1r4IwIKvuVUYQaqCZnpm4DtEYyy3LIT7h/view?usp=sharing 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/dominik-schumacher-tubulis/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:44] Entrepreneurial biotech family [00:08:46] Market validation [00:14:32] Why Munich [00:17:33] Founder-led biotechs [00:25:20] Balancing 3 kids [00:29:31] Tubulis & ADCs [00:38:25] ADC space is crowded [00:46:12] Deep Track Capital [00:48:17] Vision for Tubulis [00:52:59] ADC space is hot [00:58:03] Chinese biotech [01:02:53] Luck vs success

We’re in Boston 🇺🇸 with one of the top VCs, Otello Stampacchia of Omega Funds. We talked about the highest competitive tension in biopharma now that he has ever seen. We also talked about his career, especially the challenges and opportunities he had from moving to Boston over 15 years ago.

💎 ABOUT THE SPEAKER

Otello is the founder and managing director of Omega Funds which he started in 2004. As an investment guru, he leads the investor relations and strategic initiatives. Previously Otello led the fund investment of one of the largest private equity asset managers in the world, AlpInvest Partners. He's also been involved in many European biotechs such as Lombard Odier Immunology Fund, Goldman Sachs, and Index Securities (now Index Ventures). 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/otello-stampacchia-omega-funds/ 💸 DONATE We welcome donations from individuals and businesses to support the show and more content creation: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:57] Competitive tension in biopharma [00:14:43] Cash in pharma [00:29:19] Personal background from Italy [00:41:10] Getting into venture capital [00:51:27] Decision to move to Boston [01:01:42] Thanks for listening

Today, I’m in Paris (🇫🇷) to chat with Marc de Garidel, the new CEO of Abivax. We talk about the challenges behind the exits and why Abivax could be a third big success. 💎 ABOUT THE SPEAKER Marc is a biopharma veteran with an impressive track record. He has made two billion-dollar exits, was CEO of Ipsen, and has recently made the biggest French IPO ever with Abivax. He has also raised $60M series B for Massachusetts-based Corvidia Therapeutics before being acquired for $2.1B by Novo Nordisk. He also was the CEO of CinCor Pharma which sold for $1.8B to AstraZeneca in 2023. I’ve never met Marc but I heard many great things about him. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marc-de-garidel-abivax-exit/ 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmH LinkedIn: https://www.linkedin.com/company/flot-bio/ X (Twitter): https://x.com/FlotBio 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Wanna reach 10,000+ biotech leaders at companies like BioNTech, Immunocore or Genmab? Feel free to message Nick ([email protected]) to learn more. 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:32] Behind the scene of the 2 billion-dollar exits [00:20:48] Lessons on compliance analysis [00:24:09] What to do when the market is against you [00:36:08] Abivax: Phase II compared to standard of care [00:42:51] IBD and the microbiome [00:51:20] Why is 70% of the market in the US? [00:59:07] The best way to sell a company is to make a great product [01:03:48] Find people who inspire you [01:10:45] Thanks for listening 🙏

Today we're in Munich at BIO-Europe to chat with one of the best commentators in European biotech, Mike Ward. We talk about the best and the worst of the European biotech industry since the 80s. 💎 ABOUT THE SPEAKER Mike has been in biotech content since the birth of the industry in the 80s. He has worked at BioCentury, Informa/Scrip and now Clarivate. I’ve known Mike for many years and I like how clearly he sees things while being no-bullshit and fun. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/y428h2wr 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): [https://x.com/FlotBio 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

⏰ TIMESTAMPS [00:00:00] Intro

[00:01:32] The best and worst of biotech

[00:11:08] The beginnings of the EU biotech scene

[00:21:38] It's all in cycles and echos

[00:28:14] Biotech of today

[00:45:12] Can biotechs make money?

[00:56:31] Funding big vs small

[01:16:15] The EU biotech world is very small

[01:21:45] The changing media landscape

[01:38:35] The rockstar of biotech

[01:43:18] Thanks for listening

We’re live from Oslo 🇳🇴 to catch up with Agnete Fredriksen, co-founder and CBO of Nykode (ex-Vaccibody). In this episode, we chat about being one of the leading women in bio in Europe, the Nordics, and immunotherapies. 💎 ABOUT THE SPEAKER Agnete founded the immunotherapy company Nykode in 2006 which is now worth around $500M. For her PhD she designed and developed the first Vaccibody vaccine molecules, improving the outlook for cancer patients. I’ve known Agnete for many years and I like her sharpness while having this Scandinavian humility. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/yk364wes 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter) https://twitter.com/FlotBio

🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. These might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too.

⏰ TIMESTAMPS [00:00:00] Intro [00:00:52] Welcome [00:01:36] Women in biotech [00:25:35] Gender equality on the board [00:42:10] Raising $45 million [00:47:47] How the science works [01:01:20] Explaining the clinical results [01:07:19] The immunotherapy field [01:17:02] Biotech in Oslo [01:21:08] Thanks for listening

Biotech great Rodger Novak, Co-Founder and Chairman of CRISPR Tx joins us on the show. In this episode, we chat about bringing the first CRISPR drug to the market and why he thinks everything is wrong in bio in Europe besides science. Rodgers’ is a name everyone should know, having made it big in the global biotech scene. I first interviewed him back in 2016 at Labiotech. It’s a treat to be able to sit down with him again.

💎 ABOUT THE SPEAKER A serial entrepreneur, Rodger Novak has made it big through his many successful enterprises in the pharma and biotech scene. As co-founder of one of the hottest and best-known biotechs in the world, CRISPR Tx, he has been an instrumental player in bringing cutting-edge gene therapy to the world. Trained with a medical degree, he has also provided key contributions in the fields of anti-infectives, genetics and personalized medicine.

📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/9kucsnzt

🔗 LINKS MENTIONED: - Rodger at Hello Tomorrow 2022 - https://youtu.be/OWMRlLzJ5l8 - Rodger at Labiotech Refresh in 2019 - https://youtu.be/kp6m6BDckDk?si=RhjDeDi-n0crXMra - Rodger at Labiotech Refresh in 2016 - https://youtu.be/XFK-B1xJzGc?si=TG7ut5f-aGEgpLwg - Rodger on the Between Biotech Waves podcast - https://open.spotify.com/episode/1PFWLgJ80QmZwdN9Rmy6a7?si=0QLdSEJTSIe_et0vDarYmQ

🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://twitter.com/FlotBio

🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. These might inspire you and help you grow. 10k monthly views.

⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too.

⏰ TIMESTAMPS [00:00:00] Intro [00:00:38] Welcome [00:01:45] Bringing CRISPR to the market [00:17:33] Experience in biotech isn't everything [00:21:35] How important is CRISPR? [00:27:07] How to become best in class [00:33:40] The secret recipe for founding a successful company [00:37:28] Everything is wrong in biotech in Europe besides science [00:46:44] What can a young European founder do to bridge the US gap for biotech [00:57:01] The European attitude can get in the way of entrepreneurship [01:06:20] Follow Rodger Novak [01:09:23] Thanks for listening and follow Flot.bio

We’re back live and in Paris 🇫🇷 with our next guest, Johannes Fruehauf. We talk about reinventing the co-working labs for biotech startups, the difficulties of doing business in Europe, profitability in biotech, and much more (see timestamps below).

💎 ABOUT THE SPEAKER

Johannes is the President, CEO, and founder of BioLabs, the biggest “incubator”, or as they like to call it “co-working laboratory”, platform for biotech startups in the world. Today they have over 14 locations, including 3 in Europe (2 in Paris and 1 in Heidelberg). He is also the founder of LabCentral and a general partner at Mission BioCapital. 

📜 TRANSCRIPT

Read the full transcript here: https://tinyurl.com/mt9dva8u

🔗 FOLLOW US

- Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH

- LinkedIn: https://www.linkedin.com/company/flot-bio/

- X (Twitter): https://twitter.com/FlotBio

🎙️ ABOUT FLOT.BIO

Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views.

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too.

⏰ TIMESTAMPS

[00:00:00] Intro

[00:00:39] Welcome to this new episode

[00:02:19] How & why reinvent biotech incubators

[00:14:14] The competitors

[00:17:41] Entrepreneurship in Europe

[00:22:11] The Challenges of doing business in Europe

[00:29:37] People make it happen

[00:36:51] BioLabs in Asia and Japan

[00:41:46] Is a higher risk tolerance a good thing for everyone?

[00:48:22] Money: being profitable in life sciences and not raising money if you don't have to.

[00:59:15] Synergies between real estate and investing

[01:14:01] Should you get a business coach?

[01:25:52] Thanks for listening

In a virtual special, we welcome Bernat Olle to the show. We discuss the microbiome space, including Vedanta’s upcoming Phase 3, and how it feels to be a European founder in Boston.

Bernat is the CEO and co-founder of Boston-based Vedanta Biosciences, one of the leading microbiome companies. They’ve had a positive Phase 2 trial and recently raised a $107M round to run a Phase 3.

Bernat is a life science trailblazer. During his doctorate at MIT, he developed a novel method for large-scale bacterial culture. He's been named "Innovator of the Year in MIT Technology Review Spain's "Innovators under 35" awards and even has his own TED Talk!

I’ve known Bernat since 2013 when I was studying in Boston and he was starting Vedanta. It was great to catch up again and become inspired once more.

📜 Read the full transcript here: https://tinyurl.com/yek8ctss

🔗 Links mentioned:
Ep112: Bernat Olle on Microbiome Therapeutics - The Long Run with Like Timmerman - https://timmermanreport.com/2022/04/microbiome-based-drug-development-bernat-olle-on-the-long-run/
Ending the War on Microbes | Bernat Olle | TEDxCambridge : https://www.youtube.com/watch?v=yScP4Cm0-gE&pp=ygUQYmVybmF0IG9sbGUgdGVlZA%3D%3D

🔗 FOLLOW US
- Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://twitter.com/FlotBio

🎙️ ABOUT FLOT.BIO
Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views.

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others to find it too.

⏰ Timestamps:

(00:00:00) Intro

(00:00:56) Welcome

(00:02:36) Zooming out on the microbiome field

(00:11:44) Standardizing the process and composition

(00:21:39) What's the cost?

(00:27:16) Scalability

(00:33:05) The many microbiome companies

(00:39:43) EU microbiome industry

(00:43:51) Challenge of fundraising

(00:49:23) Running a company in the US vs EU

(01:00:30) Would you recommend the entrepreneurial path?

(01:06:04) What can I do for my microbiome?

(01:18:06) Follow Bernat

(01:19:09) Wrapping up

It’s a treat to welcome Ingmar Hoerr on the show. We chat about building a 20B dollar biotech startup, almost dying on the job, and why people skills are so important in biotech. 

Ingmar is a pioneer in the EU biotech scene, revolutionizing drug development with mRNA therapeutics. He and his team created the initial technology used in mRNA vaccines and submitted the first patents for its use. CureVac helped other mRNA companies such as Moderna and BioNTech successfully solve the Covid pandemic. Ingmar is very inspiring, as he is visionary and bold while remaining humble and caring. 

I’ve known him for almost a decade, and each interaction with him was memorable. This long episode and the lunch that followed are yet another example. Enjoy 😉

LINKS MENTIONED:

The 25 Most Valuable Biotech Companies in Europe in 2025: https://flot.bio/most-valuable-biotech-companies-europe-2025/

📜 Read the full transcript here: https://tinyurl.com/5n7d3652

🔗 FOLLOW US
- Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://twitter.com/FlotBio

🎙️ ABOUT FLOT.BIO
Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views.

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others to find it too.

⏰ Timestamps:

(00:00:00) Intro

(00:00:53) Welcome

(00:01:54) Background

(00:05:53) The mindset to make change

(00:06:59) Early days of RNA and mice

(00:08:55) The beginnings of CureVac

(00:13:39) How to survive while founding a company

(00:15:03) Where did the money come from?

(00:19:19) The key to getting the funds

(00:20:22) Getting the lab running

(00:22:34) Advancing RNA for humans

(00:24:29) Becoming a real biotech company

(00:27:31) Surviving the startup phase

(00:28:54) Investing in vision

(00:33:06) Getting proof of concept

(00:35:15) Phase one

(00:37:35) Phase two - failure is important

(00:42:51) Pharma partnerships

(00:47:01) Flu, rabies, and covid

(00:49:33) Stepping down to add in USA spirit

(00:53:01) Close to death

(00:57:49) Coming to peace with a new role

(01:02:06) The pandemic

(01:08:35) RNA people

(01:10:51) Moving on from CureVac

(01:11:53) Creating a foundation

(01:16:48) Freedom

(01:27:46) Biotech people are risk takers

(01:29:29) Sharing inspiration

(01:37:28) Reflection is key

(01:40:42) Making decisions

(01:51:37) People are important

(02:05:39) Strengths vs weakness

(02:11:32) Creating a common culture

(02:29:11) Thanks for listening

It's great to have Werner Lanthaler, the CEO of Evotec, one of the largest biotech research companies in Europe/the world, on the show. We have known each other for almost ten years now. He's not only sharp but also friendly and easy to talk to. In this episode, we chat about leading AI in biotech, the sharing economy in the industry, how to be authentic, and more. Hope it helps you learn, be inspired and grow 😉

📯 MENTIONED- Fireside chat with Werner talking about AI in Biotech in 2019 at BIO-Europe Spring in Vienna - https://www.youtube.com/watch?v=IDd1qXCsGSc&pp=ygUad2VybmVyIGxhbnRoYWxlciBsYWJpb3RlY2g%3D

- The 25 Most Valuable Biotech Companies in Europe in 2025: https://flot.bio/most-valuable-biotech-companies-europe-2025/

📜 Read the transcript here: https://tinyurl.com/p62vxwty

🔗 FOLLOW US
- Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://twitter.com/FlotBio

🎙️ ABOUT FLOT.BIO
Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views.

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others to find it too.

⏰Timestamps:

(00:00:00) Intro

(00:00:37) Welcome

(00:02:49) AI in biotech

(00:10:08) What AI means for staff

(00:11:27) How are biotech companies using AI today?

(00:15:28) Biotech - a sharing industry

(00:25:32) Trending back to integrated companies

(00:30:46) The global EU biotech industry

(00:36:03) A brighter funding future

(00:44:01) Background on Werner

(00:48:12) From no science to CEO

(00:59:04) Staying humble

(01:04:06) Mindmaps for motivation

(01:09:27) A typical day

(01:12:33) What's Evotec building?

(01:18:32) Follow Werner and Evotec

(01:19:42) Thanks for listening

(01:20:20) About Flot.bio